| Alex Twumampofo, MD | |
|
6644 E Baywood Ave, Mesa, AZ 85206-1747 | |
| (480) 981-4391 | |
| (480) 981-4624 |
| Full Name | Alex Twumampofo |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 41 Years |
| Location | 6644 E Baywood Ave, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285693663 | NPI | - | NPPES |
| 59756003 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 29669 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Gilbert Medical Center | Gilbert, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aia Hospitalists Llc | 3375583636 | 56 |
News Archive
Web-based surveillance of the global spread of SARS-CoV-2 (the virus that causes COVID-19) during the first 11 weeks of the outbreak (Dec 31, 2019, to March 10, 2020), reveals that three-quarters (75/99) of affected countries outside mainland China reported their first COVID-19 case in people who had recently travelled to an affected country-with almost two-thirds of these first cases linked to travel to Italy (27%), China (22%), or Iran (11%), according to new research published in The Lancet Infectious Diseases journal.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.
A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.
Previous infection with dengue virus may protect children from symptomatic Zika, according to a study published January 22 in the open-access journal PLOS Medicine by Eva Harris of the University of California, Berkeley, and colleagues.
› Verified 9 days ago
| Entity Name | Aia Hospitalists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831166230 PECOS PAC ID: 3375583636 Enrollment ID: O20050505000617 |
News Archive
Web-based surveillance of the global spread of SARS-CoV-2 (the virus that causes COVID-19) during the first 11 weeks of the outbreak (Dec 31, 2019, to March 10, 2020), reveals that three-quarters (75/99) of affected countries outside mainland China reported their first COVID-19 case in people who had recently travelled to an affected country-with almost two-thirds of these first cases linked to travel to Italy (27%), China (22%), or Iran (11%), according to new research published in The Lancet Infectious Diseases journal.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.
A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.
Previous infection with dengue virus may protect children from symptomatic Zika, according to a study published January 22 in the open-access journal PLOS Medicine by Eva Harris of the University of California, Berkeley, and colleagues.
› Verified 9 days ago
| Entity Name | Zion Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184049322 PECOS PAC ID: 1355566464 Enrollment ID: O20140703001618 |
News Archive
Web-based surveillance of the global spread of SARS-CoV-2 (the virus that causes COVID-19) during the first 11 weeks of the outbreak (Dec 31, 2019, to March 10, 2020), reveals that three-quarters (75/99) of affected countries outside mainland China reported their first COVID-19 case in people who had recently travelled to an affected country-with almost two-thirds of these first cases linked to travel to Italy (27%), China (22%), or Iran (11%), according to new research published in The Lancet Infectious Diseases journal.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.
A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.
Previous infection with dengue virus may protect children from symptomatic Zika, according to a study published January 22 in the open-access journal PLOS Medicine by Eva Harris of the University of California, Berkeley, and colleagues.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alex Twumampofo, MD Po Box 11773, Chandler, AZ 85248-0013 Ph: (480) 907-7707 | Alex Twumampofo, MD 6644 E Baywood Ave, Mesa, AZ 85206-1747 Ph: (480) 981-4391 |
News Archive
Web-based surveillance of the global spread of SARS-CoV-2 (the virus that causes COVID-19) during the first 11 weeks of the outbreak (Dec 31, 2019, to March 10, 2020), reveals that three-quarters (75/99) of affected countries outside mainland China reported their first COVID-19 case in people who had recently travelled to an affected country-with almost two-thirds of these first cases linked to travel to Italy (27%), China (22%), or Iran (11%), according to new research published in The Lancet Infectious Diseases journal.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.
A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.
Previous infection with dengue virus may protect children from symptomatic Zika, according to a study published January 22 in the open-access journal PLOS Medicine by Eva Harris of the University of California, Berkeley, and colleagues.
› Verified 9 days ago
Dr. Emmanuel A Bayongan, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-543-2034 Fax: 480-512-6089 | |
Dr. Sanjeev Gopal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6424 E Broadway Rd, 104-105, Mesa, AZ 85206 Phone: 602-802-8700 Fax: 602-802-8799 | |
Mouhsen H Alhakeem, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Road, Attn Amanda Gump/hospitalist, Mesa, AZ 85202 Phone: 480-412-6788 Fax: 480-412-6848 | |
Dr. Bindu Jayavelu, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 301 S Power Rd Ste 103, Mesa, AZ 85206 Phone: 480-325-7535 Fax: 480-325-7462 | |
Mr. Robert Bobek Arashahi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5652 E Baseline Rd, Mesa, AZ 85206 Phone: 480-477-7166 | |
Mr. Robert P Tully, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7525 E Broadway Rd, Ste 2, Mesa, AZ 85208 Phone: 480-981-9800 Fax: 480-985-9465 | |
Joshua D Cohen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6750 E Baywood Ave, 301, Mesa, AZ 85206 Phone: 480-835-6100 Fax: 480-461-4261 |